In combination with the observation that IL-21 has been used in a variety of clinical trials for the treatment of malignant tumours, it is necessary to further evaluate the pharmacological and physiological effects of IL-21 in the field of non-Hodgkin's lymphoma (NHL) therapy. This evidence concerns the gene IL21 and cancer.